Switch theme
Sign up to access all valuation multiples
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
2018
72
LTM Revenue $5.3M
LTM EBITDA -$47.7M
$206M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Lucid Diagnostics has a last 12-month revenue (LTM) of $5.3M and a last 12-month EBITDA of -$47.7M.
In the most recent fiscal year, Lucid Diagnostics achieved revenue of $4.3M and an EBITDA of -$44.3M.
Lucid Diagnostics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Lucid Diagnostics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $5.3M | XXX | $4.3M | XXX | XXX | XXX |
| Gross Profit | -$1.8M | XXX | -$2.8M | XXX | XXX | XXX |
| Gross Margin | -35% | XXX | -63% | XXX | XXX | XXX |
| EBITDA | -$47.7M | XXX | -$44.3M | XXX | XXX | XXX |
| EBITDA Margin | -897% | XXX | -1020% | XXX | XXX | XXX |
| EBIT | -$45.7M | XXX | -$46.1M | XXX | XXX | XXX |
| EBIT Margin | -859% | XXX | -1060% | XXX | XXX | XXX |
| Net Profit | -$51.1M | XXX | -$45.5M | XXX | XXX | XXX |
| Net Margin | -959% | XXX | -1048% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Lucid Diagnostics's stock price is $1.
Lucid Diagnostics has current market cap of $141M, and EV of $206M.
See Lucid Diagnostics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $206M | $141M | XXX | XXX | XXX | XXX | $-0.68 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Lucid Diagnostics has market cap of $141M and EV of $206M.
Lucid Diagnostics's trades at 47.3x EV/Revenue multiple, and -4.6x EV/EBITDA.
Equity research analysts estimate Lucid Diagnostics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Lucid Diagnostics has a P/E ratio of -2.8x.
See valuation multiples for Lucid Diagnostics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $141M | XXX | $141M | XXX | XXX | XXX |
| EV (current) | $206M | XXX | $206M | XXX | XXX | XXX |
| EV/Revenue | 38.6x | XXX | 47.3x | XXX | XXX | XXX |
| EV/EBITDA | -4.3x | XXX | -4.6x | XXX | XXX | XXX |
| EV/EBIT | -4.5x | XXX | -4.5x | XXX | XXX | XXX |
| EV/Gross Profit | -111.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | -2.8x | XXX | -3.1x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -4.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialLucid Diagnostics's last 12 month revenue growth is 122%
Lucid Diagnostics's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.6M for the same period.
Lucid Diagnostics's rule of 40 is -1927% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Lucid Diagnostics's rule of X is -592% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Lucid Diagnostics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 122% | XXX | 109% | XXX | XXX | XXX |
| EBITDA Margin | -897% | XXX | -1020% | XXX | XXX | XXX |
| EBITDA Growth | -6% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -1927% | XXX | -898% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -592% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 379% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 138% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 996% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Philips | XXX | XXX | XXX | XXX | XXX | XXX |
| Perspective Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| SmartVest | XXX | XXX | XXX | XXX | XXX | XXX |
| InfuSystem | XXX | XXX | XXX | XXX | XXX | XXX |
| Myomo | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Lucid Diagnostics acquired XXX companies to date.
Last acquisition by Lucid Diagnostics was XXXXXXXX, XXXXX XXXXX XXXXXX . Lucid Diagnostics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Lucid Diagnostics founded? | Lucid Diagnostics was founded in 2018. |
| Where is Lucid Diagnostics headquartered? | Lucid Diagnostics is headquartered in United States of America. |
| How many employees does Lucid Diagnostics have? | As of today, Lucid Diagnostics has 72 employees. |
| Who is the CEO of Lucid Diagnostics? | Lucid Diagnostics's CEO is Dr. Lishan Aklog, M.D.. |
| Is Lucid Diagnostics publicy listed? | Yes, Lucid Diagnostics is a public company listed on NAS. |
| What is the stock symbol of Lucid Diagnostics? | Lucid Diagnostics trades under LUCD ticker. |
| When did Lucid Diagnostics go public? | Lucid Diagnostics went public in 2021. |
| Who are competitors of Lucid Diagnostics? | Similar companies to Lucid Diagnostics include e.g. Philips, Perspective Therapeutics, SmartVest, InfuSystem. |
| What is the current market cap of Lucid Diagnostics? | Lucid Diagnostics's current market cap is $141M |
| What is the current revenue of Lucid Diagnostics? | Lucid Diagnostics's last 12 months revenue is $5.3M. |
| What is the current revenue growth of Lucid Diagnostics? | Lucid Diagnostics revenue growth (NTM/LTM) is 122%. |
| What is the current EV/Revenue multiple of Lucid Diagnostics? | Current revenue multiple of Lucid Diagnostics is 38.6x. |
| Is Lucid Diagnostics profitable? | Yes, Lucid Diagnostics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Lucid Diagnostics? | Lucid Diagnostics's last 12 months EBITDA is -$47.7M. |
| What is Lucid Diagnostics's EBITDA margin? | Lucid Diagnostics's last 12 months EBITDA margin is -897%. |
| What is the current EV/EBITDA multiple of Lucid Diagnostics? | Current EBITDA multiple of Lucid Diagnostics is -4.3x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
